Holen Sie sich die Stockscreener-App
391.27
0.48%
-1.90
Vorhandelsmarkt:
391.94
0.67
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$393.17
Offen:
$393.065
24-Stunden-Volumen:
2.87M
Relative Volume:
1.07
Marktkapitalisierung:
$211.53B
Einnahmen:
$37.30B
Nettoeinkommen (Verlust:
$7.80B
KGV:
27.21
EPS:
14.3793
Netto-Cashflow:
$8.60B
1W Leistung:
-11.65%
1M Leistung:
-4.79%
6M Leistung:
+3.79%
1J Leistung:
+39.75%
1-Tages-Spanne:
$389.28
$395.55
1-Wochen-Bereich:
$389.28
$445.81
52-Wochen-Spanne:
$269.77
$447.03
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
391.27 | 212.56B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,124.21 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.08 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.91 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.53 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.48 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Hold |
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review By Investing.com - Investing.com Nigeria
HSBC downgrades Amgen stock rating to Hold on valuation - Investing.com
HSBC downgrades Amgen stock rating to Hold on valuation By Investing.com - Investing.com Canada
Amgen stock heads into the open after a 10.1 percent drop - ad-hoc-news.de
Amgen’s Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PR Newswire
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Me - GuruFocus
Gordon Reid's Past Picks: Amgen, Qualcomm & United Rentals - BNN Bloomberg
Amgen’s Phase III DeLLphi-305 study deliverers strong results - The Pharma Letter
Amgen's Imdelltra scores again in small cell lung cancer - pharmaphorum
Amgen stock falls sharply as trial read-through and Tavneos risk unsettle investors - ad-hoc-news.de
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension - TIKR.com
Baird Financial Group Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Amgen stock heads into the open after a 10.1% drop - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Canada
Amgen Tells 4th Circ. No Point In Keeping CareFirst Suit Alive - law360.com
Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial - WTVB
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
A Look at Amgen Inc (AMGN) After 10.1% Decline -- GF Value $365. - GuruFocus
AMGN Looks 7.5% Overvalued on GF Value™ After Late-Stage Trial C - GuruFocus
Stocks to Watch Recap: Intel, Amgen, Qualcomm, Rigetti - WSJ
Amgen slides 10% amid olpasiran read-through concerns (AMGN:NASDAQ) - Seeking Alpha
AMD, Amgen, Novartis, Qualcomn, Corning, and More Stocks That Explain Today’s Market - barrons.com
AMGN Looks 8.2% Overvalued on GF Value™ - GuruFocus
Amgen-AstraZeneca drug combo helps lung cancer patients live longer in late-stage study - Reuters
Amgen: Why Rivals' Cholesterol Drug Failure Is Bad News For The Pharma (Rating Downgrade) - Seeking Alpha
Amgen Drops 9.0% Amid Sector-Wide Selling - AlphaStreet
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000 - TradingView
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today - Benzinga
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% - finance.yahoo.com
Amgen, Salesforce Share Losses Contribute To Dow's 525-Point Fall - Moomoo
What's Going On With Amgen Stock Tuesday? - Benzinga
Amgen caught in the crossfire of Novartis' failure - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownHere's Why - MarketBeat
Amgen (NASDAQ:AMGN): What’s Driving the Fresh Market Buzz? - Kalkine Media
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday - Yahoo Finance
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
Why Amgen Stock Is Down 8.7% And What's Next After Lp(a) Drug Doubts - simplywall.st
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades - Seeking Alpha
Amgen Announces Landmark Results From The Phase 3 DeLLphi-305 Study Demonstrating Statistically Significant And Clinically Meaningful Improvement In Overall Survival With IMDELLTRA In Combination With Imfinzi Compared To Durvalumab Alone - marketscreener.com
Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis - TradingKey
Why Amgen Stock Is Getting Hit by a Novartis Trial Setback - barrons.com
AMGN Reiterated by Cantor Fitzgerald -- Price Target Maintained at $400 - GuruFocus
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly - qz.com
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):